Luxembourg-based CVC Capital Partners has introduced a new specialty pharmaceutical company called Theramex in the United Kingdom, it was reported on Friday.

The company has taken this step following the completion of its USD703m acquisition of a part of Israel-based Teva Pharmaceutical Industries' global women's health business.

Theramex will manufacture products focused on women and their health. It includes Teva's formerly-owned women's health product portfolio across contraception, fertility, menopause and osteoporosis. The company will be based in London and will commercialise a variety of innovative, branded and branded generic products in 50 countries. Some of the brands in Theramex's portfolio include Ovaleap, Zoely, Estreva, Seasonique, Actonel and Lutenyl.